Table 1 Reported adverse outcomes and follow-up periods.
Studies | Outcomes reported | Follow-up periods |
|---|---|---|
Garg9 | Death, MI, MACEs, TVR, definite and probable ST | 12 months |
Garg10 | Death, MI, revascularization, TLR, MACEs, definite or probable ST | 12 months |
Wykrzykowska11 | Death, MI, TVR, TLR, ST, MACEs | 12 months |
Yadav12 | Definite and probable ST | 30 days, 12 months |
Kim14 | Death, MI, stroke | 3 years |
Capodanno13 | Death | 2 years |
Cho15 | Death, stroke, MI, revascularization, MACCEs | 10 years |
Farooq16 | Death, stroke, MI, revascularization | 4 years |
Gannot17 | Death | 8 years |
Miyagi18 | Death, revascularization, MACEs, MI | 5 years |
Shiomi19 | Death, MI, stroke, revascularization | 5 years |